FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Coalition Backs Risk-Based Device Premarket Approach

[ Price : $8.95]

The 510(k) Coalition says FDA should ensure that the risk profile of Class 2 and Class 1 reserved medical devices justifies a prem...

Allergan Files ANDA for Generic Noxafil

[ Price : $8.95]

Allergan says it has filed an ANDA seeking approval to market posaconazole delayed-release tablets (100mg), a generic version of M...

Maisel Op Ed Defends Agency Actions on Scopes

[ Price : $8.95]

CDRH chief scientist William Maisel pens an opinion piece in USA Today, defending the agencys actions to prevent patient infection...

FDA Duchenne Muscular Dystrophy Guidance Praised

[ Price : $8.95]

Stakeholder groups praise FDA for its collaborative processing in developing a draft guidance on treatments for Duchenne muscular ...

Draft Guidance on IVDs for HPC Detection

[ Price : $8.95]

FDA posts a draft guidance on Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Det...

Octapharma Wins Expanded Labeling for Wilate

[ Price : $8.95]

FDA approves an expanded indication for Octapharmas Wilate [von Willebrand factor/coagulation factor VIII complex (human)] to incl...

FDA Extends Review on BMS Opdivo in Melanoma

[ Price : $8.95]

FDA extends by three months its target review action date on a Bristol-Myers Squibb supplemental BLA for Opdivo.

FDA Approves Oxycontin for Pediatric Use

[ Price : $8.95]

FDA approves Purdue Pharmas Oxycontin (oxycodone hydrochloride) extended-release tablets for use in pediatric patients aged 11 to ...

FDA Touts Device Review Improvements

[ Price : $8.95]

An FDA report claims credit for many improvements to the medical device review process in the last five years.

Nimodipine Capsules Not for IV Use, FDA Says

[ Price : $8.95]

FDA reiterates its caution that nimodipine should never be administered intravenously.